All News

Pharmacy Times spoke with Dr. Mark Pollack, MD, about Mental Health Awareness Month and the latest information on depression/medication adherence.

Pharmacy Times spoke with Tomas Villanueva, DO, MBA, FACPE, SFHM, practicing health care provider, and associate vice president for clinical resources at Vizient, about how hospitals are tailoring their approaches to vaccine hesitancy to address social detriments.

While the exact reason for the decreased immune response in middle-aged adults remains unclear, these findings suggest that this patient population may be continuously susceptible to the 3c2A H3N2 infection, even with immunization.

The investigational therapy RBX2660 has demonstrated positive trends in efficacy and safety for reducing recurrent Clostridioides difficile (C. difficile) infection over 6 months, in a recent study.

Lynlee Burton, head of the Center for Vaccines and Emerging Infectious Diseases at PRA Health Sciences, discusses how the pandemic has impacted the way the United States views the pharmacist within the immunization space.

Jay Lieberman, MD, a pediatric infectious disease specialist and the senior medical director of PRA Health Sciences, discusses how health care professionals should approach discussing issues around vaccine hesitancy with parents.

This month's featured products include dapagliflozin, naloxone hydrochloride spray, and short ragweed pollen allergen extract.

Susan Lang, CEO of XIL Health and former senior executive at Express Scripts, discusses some of the reimbursement issues that have been arising for pharmacies while administering COVID-19 vaccines.

In the 18th century, Franz Friedrich Anton Mesmer introduced the healing power of animal magnetism to Europe.

How should pharmacists help these patients?

Rimegepant is indicated for adult patients with episodic migraines.

Adverse effects from intravenous immunoglobulin tend to be mild, but moderate and severe adverse effects have been observed.

Lynlee Burton, head of the Center for Vaccines and Emerging Infectious Diseases at PRA Health Sciences, discusses the significance of short vaccine development timelines on the future development of COVID-19 vaccines.

Jay Lieberman, MD, a pediatric infectious disease specialist and the senior medical director of PRA Health Sciences, discusses his decision to enroll his twin daughters in the Moderna COVID-19 vaccine trial.

Susan Lang, CEO of XIL Health and former senior executive at Express Scripts, discusses the impact of declining reimbursements on pharmacies that were already hard hit by the COVID-19 pandemic.

A recent article from the American Cancer Society reports a mixed picture, with historic lows in smoking prevalence but suboptimal obesity, cancer screening, and HPV vaccination levels.

The legislation would require that patients with cancer have access to oral oncology drugs within 72 hours of having the prescription submitted to the patient’s pharmacy benefits manager.

Patients who added dupilumab to standard of care saw a 65% reduction in the rate of severe asthma attacks over 1 year.

Pharmacists should counsel patients periodically to ensure correct usage for better disease and treatment management.

The researchers analyzed immunization records for more than 300,000 Texas children from birth to 24 months.

David Silverstein, JD, MS, a partner in Axinn’s Intellectual Property Practice Group and FDA practice groups, discusses the challenges posed by the White House’s support for the proposal to the WTO to waive IP protections for COVID-19 vaccines.

Incidence rates of early-onset colorectal cancer in the United States have increased from 8.6 to 13.1 per 100,000 between 1992 and 2013, with most of this increase attributable to early-onset cancers of the rectum.

Jay Lieberman, MD, a pediatric infectious disease specialist and the senior medical director of PRA Health Sciences, on the future of COVID-19 disease and vaccines for adolescents and children.

During a recent roundtable discussion, industry leaders shared frontline insights on the biggest drug diversion challenges.

Other HPV-associated cancers were found to have increased over the study period, linking this trend to lack of guidelines and other resources.

Inhibiting Toll-like receptor 4 stopped it from accumulating cisplatin, thereby halting the hearing damage caused by the cancer treatment.

The researchers are hopeful this could eventually lead to the elimination of long-term antiretroviral treatment as a lifelong necessity for patients with HIV.